| Literature DB >> 25426209 |
Gabriele Poggensee1, Ndadilnasiya Endie Waziri1, Adebobola Bashorun2, Patrick Mboya Nguku1, Olufunmilayo Ibitola Fawole3, Kabir Sabitu4.
Abstract
In Nigeria the current prevalence of HIV is 4.1% with over 3.5 million infected and estimated 1.5 million in need of anti-retroviral treatment. Epidemiological and implementation studies are necessary for monitoring and evaluation of interventions. To define research areas which can be addressed by participants of the Nigeria Field Epidemiology and Training Programme (NFELTP) a workshop was held in April 2013 in Abuja, Nigeria. Priority research areas were identified using criteria lists for ranking of the relevance of research questions. Based on a research matrix, NFELTP residents developed the aims and objectives, study design for HIV-related research proposals. This workshop was the first workshop held by the NFELTP to establish an inventory of research questions which can be addressed by the residents within their training period. This inventory will help to increase HIV/AIDS-related activities of NFELTP which are in accordance with research needs in Nigeria and PEPFAR objectives.Entities:
Keywords: HIV/AIDS; Nigeria; Research priorities; field epidemiology; training programme; workshop
Mesh:
Year: 2014 PMID: 25426209 PMCID: PMC4242107 DOI: 10.11604/pamj.2014.18.262.4804
Source DB: PubMed Journal: Pan Afr Med J
Summary of the 20 HIV/AIDS-research questions with the highest average scores based on the pre-workshop questionnaire (lines highlighted in grey: more than 10% of the respondents were undecided to give high or low priority).
| Research areas | Topics | Undecided (%) | Average |
|---|---|---|---|
| General | Implementation research | 6,9 | 1,07 |
| General | HIV prevention, general | 0,0 | 1,24 |
| HIV andtuberculosis | Studies on provision of screening of TB patients for HIV | 0,0 | 1,21 |
| HIV andtuberculosis | Identification of best strategies for the co-management of TB and HIV care | 0,0 | 1,29 |
| HIV Care | Paediatriccoverage | 3,7 | 1,14 |
| HIV Care | Identification of socio-economic, behavioural, cultural, structural and other factors that have an impact on ART access and can be influenced by the programme | 3,7 | 1,17 |
| HIV epidemiology | Proportion of individuals becoming newly infected (incidence) | 3,6 | 1,11 |
| HIV prevention | Evaluation of combination of prevention approaches | 3,4 | 1,24 |
| Monitoring, datausage | Comprehensive inventory of publicly available data on HIV/AIDS | 7,1 | 1,24 |
| Monitoring, datausage | Studies on utilization of data | 0,0 | 1,28 |
| PMTCT | Evaluation of combination of prevention approaches | 0,0 | 1,28 |
| PMTCT | Early infant diagnosis – what is the proportion of mothers receiving test results | 7.1 | 1.32 |
| HIV care | Screening for cervical intraepithelial lesions (PAP) | 25,0 | 1,14 |
| HIV care | Contributionof private sector | 14,8 | 1,28 |
| HIV epidemiology | Numbers of individuals requiring ART | 10,7 | 1,29 |
| HIV support | Have workplace programs affected stigma and discrimination at the workplace | 29,6 | 1,03 |
| HIV support | To what extent does access to treatment promote HIV disclosure? | 10,7 | 1,24 |
| PMTCT | Identification of best strategies for provision and monitoring of CD4 testing and treatment for pregnant and breastfeeding women | 10,7 | 1,18 |
| PMTCT | Factors influencing the retention of care in the first 12 months of life | 14,3 | 1,29 |
| PMTCT | To what extent are recommendations regarding feeding options are understood by the service providers at different levels in the health delivery system | 32,1 | 1,29 |
PMTCT/EID-related research questions
| Area | Research questions |
|---|---|
|
| What strategies can influence acceptance and uptake of PMTCT services? |
| What community strategies can effectively increase PMTCT uptake? | |
| What are the strategies to ensure retention of pregnant women throughout the PMTCT cascade especially delivery in health facilities? | |
| What are the roles of community women (e.g. market women) in PMTCT? | |
| What are the socio-cultural (religious) factors that hinder access to PMTCT services? | |
| What is the role of male involvement in PMTCT? | |
| What is the availability of uniform PMTCT protocols? | |
| What are the challenge of integration of PMTCT services and conventional health services? | |
|
| What are the factors that influence the decision on HIV positive pregnant women to get pregnant? |
| What are the contraceptive needs and choices of HIV positive women of reproductive age group? | |
|
| Why do women prefer to deliver with TBAs? |
| What can be the roles of the traditional birth attendants in PMTCT? | |
| What is the role of the private sector in PMTCT? | |
|
| How best can HIV positive pregnant women be supported to adhere with their chosen infant feeding methods? |
|
| How to ensure provision of early detection and confirmatory test facilities at all levels of care? |
| What is the level HIV drug resistance in HIV-positive children in Nigeria? |
Identified research areas for HIV care and support
| Area | Research topics |
|---|---|
|
| What clinical and/ or laboratory approaches can be employed to optimize diagnoses of HIV/AIDS? |
| What is the best time and method of disclosure to paediatric and adolescent patients (sero-discordant couples, polygamous setups)? | |
| What are the determinants of the poor linkage from testing to enrolment in care and treatment? | |
| How do we improve HCT uptake to meet the target of presidential order of putting 400,000 new PLWAs on ART? | |
|
| What are the challenges and barriers to treatment seeking among different populations of PLWA? |
| What is/are the best model(s) for delivering ART services, e.g. de-centralization & integration of ART services with other services? | |
| What are the determinants for default of ART? What is the best treatment model for optimal adherence; Facility based or community based? | |
| How can resources for monitoring ART be optimized,e.g. use of targeted viral load? | |
| What treatment regimens are most potent, cost effective and improve adherence? | |
| What is the contribution of private health facilities to ART services in Nigeria; what are the quality and spectrum of services rendered? | |
| ARV drug resistance, what are the early warning signs from facilities? | |
| Efavirenz and teratogenicity; are there cases associated with teratogenicity in past? | |
| What is the prevalence of HIV-related malignancies; what is their impact on presentation? | |
| What is the prevalence of co-infection in certain groups /sub-populations, e.g. prisoners, (para) military, and high at risk groups? | |
|
| How can the diagnosis of opportunistic infections be optimized? What clinical or lab approaches (biomarkers, clinical algorithm)? |
| What is the impact of high attrition of trained health care workers on ART services? Doesitaffect Quality of care? | |
| What protection and support strategies are available for health care workers; what is the outcome of post exposure prophylaxis (PEP)? | |
|
| What are the prospects and challenges of integration of HIV/AIDs treatment into mainstream clinical services? |
| Do healthcare workers use the national guidelines for HIV/AIDs treatment? | |
| What system of quality improvement for care is in place? Is it working well? Has it improve quality of care? Whatarethechallenges? | |
| Community home-based care: what is the quality? What are the sources and channel of resources? | |
| What are the models of ART services decentralization in Nigeria and their effectiveness? | |
| How to enhancing the success rate of community-based referral system in linking HIV positive people with treatment centres? | |
| Expanding the provision of ART And PMTCT services through engagement of private health facilities in the national HIV response in Nigeria | |
|
| What is impact on drugs delivery and consumables supply? What are the challenges? How have tjese factors affected quality of care? |
| What is the level HIV drug resistance in HIV-positive children in Nigeria? |
Epidemiology and Surveillance gaps for HIV/AIDS
| Research area | Topic |
|---|---|
|
| What data dissemination plans are in place? |
|
| What are the determinants of limited activities in STI surveillance? |
| What are the challenges of the AIDS case reporting system? | |
| What is the HIV prevalence among health care providers at hospitals? | |
| What are the factors contributing to the different HIV prevalence on the state level? | |
| How can a HIV drug resistance surveillance system be established? | |
|
| What are the factors associated with high and low HIV prevalence rates at ANC sentinel sites? |
| What is the association between HCT services uptake and the epidemiology of HIV/AIDS among women attending ANC in high and low sentinel sites in Nigeria? | |
| What factors are associated with high or low epidemics in four highest and lowest sentinel sites in Nigeria? |
Research questions identified for HIV-TB-co-infection
| Area | Research topics |
|---|---|
|
| How to improve diagnosis of tuberculosis among HIV infected individual? |
| What is extent of Isoniazid preventive therapy (IPT) coverage? What are the challenges of instituting IPT? | |
| What is the burden of and diagnostic challenges of non-tuberculous mycobacterium among HIV-infected individuals? | |
| What are the best strategies for co-management and referral for TB and HIV cases after diagnosis? | |
| What are the TB type and molecular characterics among HIV positive TB patients? | |
|
| What is the extent of TB-HIV service integration? What models are being used and what are the challenges to optimal integration of these services? |
| What is the level of TB infection control in our ART facilities? What are the challenges in TB infection control? | |
| Are there infection control committees & guidelines in place? | |
|
| How do we improve adherence to medications in patients with TB/HIV/Hepatitis B? Can provision of DOTS (at facility and community levels) improve outcome of treatment? Does provision of treatment to partner improve outcome? |
| How do we reduce attrition rates in our ART programs? What factors contribute to this? How do we tract these patients? How do we optimize retention of these patients within the programs? | |
| What is the treatment success rate of TB-treatment in PLWAs? | |
| What are socio-economic and socio-cultural factors hindering co-treatment of TB and HIV? | |
| What are the determinants of the high rate of loss to follow-up? How do we tract the patient (phone number)? | |
| What are the challenges to the provision of ART/PMTCT services in private health facilities? | |
|
| What is the burden of HIV-drug resistance and Drug resistant TB(DR-TB)? |
| What are the challenges in TB-HIV co-infection management in the presence drug resistance? | |
|
| What is the outcome of managing TB-HIV co-infection in the presence of hepatitis? Whatarethechallengesoftreatment? |
|
| What is the role played by patients support groups in improving socio-economic status of PLWAs? |
Scoring of HIV/AIDS-related research questions
| Research area | Research topic | Average scoring |
|---|---|---|
|
| Investigation of socio-cultural and religious factors hindering access to PMTCT services | 6.6 |
| Assessment of the provision of early detection and confirmatory test in health facilities | 6.4 | |
| Identification of best strategies for the provision and monitoring of CD4 test and treatment during pregnancy and breastfeeding | 6.2 | |
| Determination of uptake of PMTCT | 6.1 | |
| Factors that determine acceptance of exclusive breastfeeding among HIV-positive mothers | 5.5 | |
|
| Incidenceof MDR-TB | 8.4 |
| Assessment of TB treatment success in HIV-positive patients | 7.4 | |
| Socio-economic and socio-cultural factors hindering the co-management of TB and HIV | 6.7 | |
|
| Assessment of challenges of optimizing quality in care | 8.0 |
| Factors associated with adherence to antiretroviral drugs | 7.9 | |
| What are the contributions of the private health sector to ART services | 7.9 | |
| What are the challenges and prospects of optimizing gene expert in TB diagnosis among TB suspect HIV positive patients? | 7.8 | |
| Pharmacovigilance: What is the level of integration in ART services in Nigeria? | 7.8 | |
| What are the factors associated with compliance to National Guidelines? | 7.7 | |
| What are the outcomes and challenges of post-exposure prophylaxis among health care workers? | 7.6 | |
| What are the challenges of IPT utilization in ART facilities? | 7.6 |